Navigation Links
Caprion Awarded US $12.9M Infectious Disease Biomarker Research Contract
Date:10/6/2008

MONTREAL, Oct. 6 /PRNewswire/ -- Caprion Proteomics Inc. announced today that it has been awarded a $12.9 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the US National Institutes of Health, to carry out Biodefense research in the area of infectious disease biomarkers.

Under the contract to be performed over a five-year period, Caprion will act as one of two NIAID Clinical Proteomics Centers for Infectious Disease & Biodefense, and will employ its distinctive CellCarta(R) quantitative protein profiling technologies to perform several large scale applied proteomics projects using human clinical samples from patients with infectious diseases. The projects will be aimed at the discovery, qualification, and verification of candidate biomarkers with potential for clinical use to improve detection and diagnosis and to monitor therapeutic and vaccine responses and susceptibility to infection for diseases caused by various pathogens. This second major Biodefense research contract awarded to Caprion by NIAID builds on the expertise and results demonstrated by Caprion as part of an initial contract awarded in 2004 and still in progress.

"We are very pleased to be granted the opportunity to expand our infectious disease research program with NIAID into the area of clinical biomarker discovery and validation," said Martin LeBlanc, President and CEO at Caprion. "This second major contract award from the NIAID provides further evidence of Caprion's solid scientific capabilities and industry leadership position as a proteomics and biomarker services provider."

Caprion will retain rights to commercialize candidate biomarkers and diagnostic products discovered in this project.

About Caprion Proteomics, Inc.

Caprion Proteomics is the leading provider of proteomics based services to the pharmaceutical industry. Caprion's proprietary proteomics discovery technology, CellCarta(R), is a gel-free, label-free mass spectrometry platform that enables a comprehensive, quantitative and robust measurement of the protein expression differences across large sets of biological samples. Caprion has been providing biomarker and target identification services since 2002, and has served such clients as Pfizer, Johnson & Johnson, Abbott Laboratories, Biogen Idec, Daiichi-Sankyo, Mitsubishi-Tanabe, Wyeth, AstraZeneca, Merck, Boehringer Ingelheim, ICOS, Bayer-Schering, EMD-Serono, Vertex, DebioPharm and Transgene. Caprion also has been awarded two major 5-year Biodefense proteomics research contracts in infectious disease with the NIH-NIAID. For more information, please visit: http://www.caprion.com.

Contact:

Didier Jean-Francois

(514) 228-3625

dfrancois@caprion.com


'/>"/>
SOURCE Caprion Proteomics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SpectraScience Awarded Patent for Its Optical Biopsy System and Methods for Tissue Diagnosis
2. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
3. GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA
4. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
5. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
6. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
7. Dr. Yong Shi awarded NSF grant
8. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
9. BioNanomatrix Awarded New NIH Grant for Development of Nanoscale Platform for Single-Molecule DNA Mapping and Haplotype Applications
10. U.S. Genomics Awarded $9.1 Million Contract for Development of Advanced Biosensor by the U.S. Department of Homeland Security
11. ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... ... market news outlet had provided a research update on Aytu Bioscience and cited ... product. , According to Soulstring, prescription rates for Natesto® have more than doubled ...
(Date:8/16/2017)... ... 16, 2017 , ... Tunnell Consulting announced today that four of ... Annual Meeting and Expo , to be held October 29 through November 1 in ... innovation to advance patient therapies.” , The ISPE Annual Meeting and Expo will feature ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... a different cell type. Many treatments for specific cancers, such as breast, prostate, ... targeted treatment is androgen deprivation therapy for advanced prostate cancer. , This ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... beneficial microbe delivery system, announced it has secured $2M in funding from an ... City Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar is ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):